Related Experiment Video
Updated: Jun 24, 2026

Protocol to Create Chronic Wounds in Diabetic Mice
Published on: September 25, 2019
Onychomycosis and diabetes
S Cathcart1, W Cantrell, B e Elewski
1Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA. scathcart@uabmc.edu
Objective:
This study aims to discuss factors specific to diabetics in the diagnosis and treatment of onychomycosis.
Discussion:
Onychomycosis has the potential to cause severe complications in diabetics and should be treated promptly. The existence of comorbid conditions and potential for drug-drug interactions complicates the selection of an appropriate treatment regimen. The role of Candida in onychomycosis is controversial but may be of increased significance in the diabetic population due to an underlying vulnerability to this organism.
Conclusions:
Terbinafine is an excellent choice in diabetics due to its low risk of drug-drug interaction and proven efficacy against the typical pathogens that cause onychomycosis. Itraconazole, while an effective treatment for onychomycosis, is not a first-choice therapy due to its black-box cardiac warning and numerous drug interactions. Larger studies are needed in diabetics to determine the frequency of candidal nail infections.
Related Concept Videos
Complications of Diabetes Mellitus
Diabetic Foot Ulcer
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Type I Diabetes II: Pathophysiology
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type II Diabetes II: Pathophysiology
